You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-T cell antibodies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Anti-Argonaute Antibodies for Diagnosis of Sensory

Completed
  • Autoimmune Diseases
  • Diagnosis of sensitive neuronopathy - phase 1
  • +4 more
  • Saint-Étienne, France
    CHU Saint-Etienne
Jul 27, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))

Recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital Zhejiang University School of Medi
May 11, 2023

Solid Tumor Trial (UCLM802 Cell Injection)

Not yet recruiting
  • Solid Tumor
  • UCLM802 Cell Injection
  • (no location specified)
Mar 7, 2023

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

Follicular Lymphoma, Mantle Cell Lymphoma Trial in Rouen (Determination of COVID-19 vacciantion efficacy)

Completed
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Determination of COVID-19 vacciantion efficacy
  • Rouen, France
    Centre Henri Becquerel
Dec 22, 2022

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New

Recruiting
  • Mantle-cell Lymphoma
  • B Cell Chronic Lymphocytic Leukemia
    • Monza, MB, Italy
      Andrea Aroldi
    May 24, 2023

    B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

    Recruiting
    • B-Cell Leukemia
    • +2 more
    • Anti-CD19 Autologous CAR-T Cell Infusion
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force of People's Libe
    Jul 9, 2023

    Oral Care of Patients Treated With Anti-RANK-ligand Antibodies

    Recruiting
    • Giant Cell Tumors
      • Strasbourg, France
        Service de Médecine et Chirurgie Bucco-Dentaires - CHU de Strasb
      Sep 12, 2022

      Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)

      Not yet recruiting
      • Carcinoma
      • Intravenous infusion anti-CEA-CAR-T cell
      • (no location specified)
      Aug 22, 2023

      Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

      Completed
      • Metastatic Colorectal Adenocarcinoma
      • regorafenib plus anti-PD-1 antibodies
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Jul 4, 2023

      Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections Trial in Pittsburgh (Specific T- Lymphocytes)

      Not yet recruiting
      • Adenovirus
      • +2 more
      • Specific T- Lymphocytes
      • Pittsburgh, Pennsylvania
        UPMC Children's Hospital of Pittsburgh
      Sep 8, 2023

      B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

      Recruiting
      • B-cell Lymphoma
      • ASCT+CAR-T Cell Infusion
      • Xuzhou, Jiangsu, China
        The Affiliated Hospital of Xuzhou Medical University
      Feb 23, 2023

      Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

      Not yet recruiting
      • Solid Tumor
      • Intravenous infusion anti-HER2-CAR-T cell
      • Shenyang, Liaoning, China
        Phase I Clinical Trials Center Of The First Hospital of China Me
      Oct 30, 2023

      Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

      Not yet recruiting
      • Pediatric Cancer
      • +11 more
      • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
      • Milwaukee, Wisconsin
        Children's Wisconsin
      Sep 14, 2022

      Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

      Recruiting
      • Lymphoma, Non-Hodgkin
      • Lymphoma, T-Cell
      • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
      • Najing, Jiangsu, China
        Jiangsu Provincial People's Hospital
      Sep 26, 2022

      Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • Zhengzhou, Henan, China
        Henan Cancer Hospital
      Jul 18, 2023